Informopedia Explains: imagine a vaccine that only works for you — not because you are special, but because it was literally manufactured from your own tumour. That is what a personalised cancer vaccine is, and this month it passed the most important test in medicine: a large, randomised phase 3 trial.
Start with the problem it solves. When surgeons remove a melanoma — the deadliest form of skin cancer — the visible tumour is gone, but stray cancer cells can remain, invisible, elsewhere in the body. Months or years later, they can grow back. Even with modern immunotherapy drugs, many patients see their cancer return. The question researchers have chased for decades is whether the immune system can be taught to hunt those specific leftover cells before they get the chance.
A wanted poster made from your tumour
Every tumour carries mutations — spelling mistakes in its DNA that healthy cells do not have. Some of those mistakes create new protein fragments, called neoantigens, that appear on the surface of cancer cells like flags. A personalised vaccine is built from those flags. Doctors sequence the removed tumour, compare it with the patient’s healthy DNA, and pick the mutations most likely to provoke an immune response. The vaccine then carries the instructions for up to 34 of those neoantigens — in the case of intismeran, the vaccine at the centre of this month’s news — encoded as messenger RNA, the same technology behind some COVID-19 vaccines.
Lead researcher Professor Georgina Long, of Melanoma Institute Australia, described the idea in plain terms: the tumour’s genetic “fingerprint” is read by sequencing, “then a ‘wanted poster’ of the cancer is made as mRNA, showing the immune system exactly what to look for and attack”. Injected into the patient, the mRNA instructs cells to build those neoantigen fragments, training T-cells — the immune system’s hunters — to recognise and kill any cell carrying them. It is given alongside pembrolizumab (Keytruda), a drug that stops cancer cells from switching the immune response off.
What the trial actually showed
The INTerpath-001 trial enrolled 1,137 adults whose stage IIB to IV melanomas had been completely removed by surgery. Two-thirds received intismeran plus pembrolizumab; the rest received a placebo plus pembrolizumab. After a median follow-up of 24.6 months, the combination cut the risk of recurrence or death by 42% compared with pembrolizumab alone. The risk of distant metastasis — cancer spreading to far parts of the body — or death fell by 38%. After two years, 82.2% of patients on the combination had not seen their cancer return, against 70% on pembrolizumab alone. The results were presented at the European Society for Medical Oncology congress in Madrid and have been accepted for publication in the New England Journal of Medicine — the first phase 3 trial to show this kind of benefit for a personalised approach in melanoma.
It is also worth noting what the trial did not show. Overall survival — whether patients actually live longer, rather than just longer without recurrence — has not yet been proven, and the benefit took time to emerge: the two groups performed similarly in the first six months, with the advantage widening only after patients completed the vaccine schedule, which fits the biology — training an immune response takes time. Analysts also noted the result, while statistically strong, was at the modest end of what some had hoped for after an earlier, smaller trial.
What it cannot do — yet
First, this is treatment, not prevention. A personalised cancer vaccine cannot stop you getting cancer; it can only be made after a tumour exists to sequence. Second, it is slow and expensive by vaccine standards: each dose is a bespoke manufacturing run for one patient, which raises hard questions about cost, waiting times and access if the approach spreads to other cancers. Third, melanoma was a favourable test case — it carries many mutations, which means many neoantigens to choose from. Cancers with few mutations may prove harder targets, and researchers are now testing the approach in other tumour types and earlier settings.
None of that diminishes what happened in Madrid. For decades, cancer treatment was defined by where a tumour started — lung, breast, skin. INTerpath-001 supports a different idea: treatment defined by the unique mutational signature of the patient’s own tumour. If that idea holds up in other cancers, the vaccine of the future may not come off a shelf at all. It may come out of a sequencing machine, made for one person, and one person only.
